17,261 trials
Molluscum Contagiosum
Primary: The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following…
Adenoid Cystic Carcinoma
Primary: Best Overall Response Rate — 0; 0; 11; 5 Participants
Cannabis Use Disorder
Primary: Time to Cannabis Use Relapse — 1; 1 days
Diabetes
Primary: Change in HBA1c From Baseline — 1.42; 1.34 %mmHg/dL
Postherpetic Neuralgia
Primary: Mean Pain Score on Daily Pain Rating Scale (DPRS) — 4.32; 4.22; 5.57 units on a scale — p=0.3910
Candidemia
Primary: Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC) — 16 Participants
Metastatic Melanoma
Primary: Response Rate: The Number of Participants Who Completed the Maximum Time Allowed on Study Without Being Affected by Tumor Recurrence or Progression. — 0 Participants
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
Lichen Planus
Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale
Psoriatic Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16 — 43.28; 64.52; 66.67; 74.58 Percentage of participants — p=0.1172
Myasthenia Gravis
Primary: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9 — -1.2; -1.8 scores on a scale — p==0.221
Metastatic Thyroid Gland Carcinoma · Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma
Primary: Response at 6 Months — 7; 2 Participants — p=0.0787
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Clinical Benefit Rate [CBR] — 12 Participants
Anemia, Sickle Cell
Primary: C-Reactive Protein — 11.4; 6.8 mg/l
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathological Response (MPR) — 2; 16 Participants — p=0.0001